Dan is a corporate and securities attorney whose practice spans the full gamut of corporate law. He has advised clients for over two decades in public and private equity and debt financings, securities law matters, mergers and acquisitions, and strategic advice on a broad range of other corporate matters. He capably counsels public and private companies with offerings, compliance, and securities questions and leads buyers and sellers throughout the transaction process. Dan represents life sciences companies as well as clients in other technology fields, financial services, and professional services firms.
Dan’s practice focuses primarily on venture finance, securities law and offerings, mergers and acquisitions, and general business and corporate law, primarily for life sciences and technology companies.
VCs, strategic investors, and issuers rely on Dan’s extensive experience in private fund raising, including equity and debt financings. Public companies also turn to him in connection with public and private offerings and their securities law and compliance needs. In addition, both buyers and sellers engage Dan to counsel them in complicated mergers and acquisitions. Dan also regularly advises both private and public companies at various stages of development on general corporate matters.
Prior to joining the firm, Dan served as a law clerk to the justices of the Superior Court of Massachusetts. While in law school, he served as a staff author and comment editor for the Suffolk University Law Review.
Dan is a corporate and securities attorney whose practice spans the full gamut of corporate law. He has advised clients for over two decades in public and private equity and debt financings, securities law matters, mergers and acquisitions, and strategic advice on a broad range of other corporate matters. He capably counsels public and private companies with offerings, compliance, and securities questions and leads buyers and sellers throughout the transaction process. Dan represents life sciences companies as well as clients in other technology fields, financial services, and professional services firms.
Experience
Offerings for Public Companies
- Represented Vertex Pharmaceuticals (Nasdaq: VRTX) in over $2.0 billion in equity and debt offerings since 2006
- Represented ImmunoGen (Nasdaq: IMGN) in approximately $350 million in equity offerings since 2008
- Represented Amedica (Nasdaq: AMDA) in its IPO
- Represented the underwriters in the IPO of Calithera Biosciences (Nasdaq: CALA)
- Represented the underwriters in the IPO of American Depositary Shares of GW Pharmaceuticals (Nasdaq: GWPH) and two additional follow-on offerings
Venture Capital & Strategic Financings
- Represented a public technology company in the semiconductor and life sciences industry (Nasdaq) in multiple strategic investments
- Represented a public medical device company (NYSE) in multiple strategic investments
- Represented Clarus Ventures in its investments in Ophthotech (Nasdaq: OPHT), VBI Vaccines (Nasdaq: VBIV), TyRx Pharma, and Link Medicine
- Represented a public biotechnology company (Nasdaq) in its strategic equity investment in a private biotechnology company
- Represented Style Me Pretty in its strategic investment from AOL (NYSE: AOL)
- Represented Synchroneuron in multiple equity financings
- Represented TransMolecular in multiple equity and debt financings
- Represented Ion Torrent Systems in multiple equity financings
- Represented I-Pulse in multiple equity financings
- Represented TransForm Pharmaceuticals in multiple equity financings
- Represented Hemera Biosciences in its Series A financing
Mergers & Acquisitions
- Represented Brooks Automation (Nasdaq: BRKS) in its purchase of BioStorage Technologies
- Represented a public biotechnology company (Nasdaq) in its entering into a merger option to acquire a private biotechnology company
- Represented Clarus Ventures in the reverse merger of VBI Vaccines (Nasdaq: VBIV) with Paulson Capital
- Represented Orchid BioSciences (Nasdaq: ORCH) in its sale to Laboratory Corporation of America (NYSE: LH)
- Represented QIAGEN (Nasdaq: QGEN) in its purchase of SA Biosciences
- Represented TransMolecular in its sale to Morphotek (a subsidiary of Eisai Co. (Tokyo Stock Exchange))
- Represented Auspice in its sale to the ARRIS Group (Nasdaq: ARRS)
- Represented EPIX Pharmaceuticals (Nasdaq: EPIX) in its merger with Predix Pharmaceuticals
- Represented TransForm Pharmaceuticals in its sale to Johnson & Johnson (NYSE: JNJ)
- Represented FastClick (Nasdaq: FSTC) in its sale to ValueClick (Nasdaq: VCLK)
viewpoints
Section 16 Insider Reporting to Apply to Foreign Private Issuers Beginning March 18, 2026
December 22, 2025 | Alert | By Anne Bruno, Daniel T. Kajunski, Allyson Wilkinson
Effective March 18, 2026, directors and officers of U.S.-listed companies that qualify as foreign private issuers (FPIs) will be required to publicly report their equity holdings and transactions pursuant to Section 16(a) of the Securities Exchange Act of 1934 (Exchange Act). This change stems from Congress’ passage of the National Defense Authorization Act for Fiscal Year 2026 (NDAA), which President Trump signed into law on December 18, 2025.
Preparation for 2025 Fiscal Year-End SEC Filings and 2026 Annual Shareholder Meetings
December 18, 2025 | Advisory | By Anne Bruno, Daniel T. Kajunski, Melanie Ruthrauff Levy, Page R. Hubben, Joanne Hawana , Jacob Hupart, Breton Leone-Quick, Jennifer Rubin, Benjamin Zegarelli, Nicole Rivers
Prepare for 2025 fiscal year-end SEC filings and 2026 shareholder meetings with Mintz’s insights on evolving disclosure requirements, AI and cybersecurity risks, climate reporting, proxy advisory updates, and FDA regulatory changes.
SEC Roundtable on Executive Compensation Disclosure
July 23, 2025 | Advisory | By Amanda Mei, Daniel T. Kajunski, Anne Bruno
The SEC held a roundtable at the SEC’s headquarters in Washington, DC on June 26, 2025 to discuss possible changes to the Commission’s requirements for executive compensation disclosure.
Preparation for 2024 Fiscal Year-End SEC Filings and 2025 Annual Shareholder Meetings
December 17, 2024 | Advisory | By Anne Bruno, Daniel T. Kajunski, Melanie Ruthrauff Levy, Page R. Hubben, David Adams, Joanne Hawana , Jacob Hupart, Cynthia Larose, Breton Leone-Quick, Benjamin Zegarelli, Christopher Buontempo
Every year, Mintz provides analysis of the regulatory developments affecting public companies as they approach fiscal year-end filings with the Securities and Exchange Commission and annual shareholder meetings. This memorandum highlights key considerations to guide you through the 2025 year-end reporting process.
SEC Approves Nasdaq Rule Change on Reverse Stock Splits and Minimum Bid Price Compliance Timing
October 17, 2024 | Alert | By Page R. Hubben, Anne Bruno, Daniel T. Kajunski
Read about an amendment to Nasdaq Listing Rule 5810(c)(3)(A), approved by the SEC on October 7, 2024, which affects companies utilizing reverse stock splits to regain compliance with Nasdaq’s minimum bid price requirements.
New Schedule 13G Accelerated Filing Deadlines Effective Today, September 30, 2024
September 30, 2024 | Alert | By Page R. Hubben, Daniel T. Kajunski, Anne Bruno
Read about the new accelerated filing deadlines for ownership reporting on Schedule 13G that take effect on September 30, 2024 and the requirements for different types of investors.
SEC Issues Updated Guidance on Cybersecurity Incident Disclosure Under Item 1.05 of Form 8-K
July 11, 2024 | Alert | By Daniel T. Kajunski, Anne Bruno, Kevin M. Yao
The SEC issued five new Compliance & Disclosure Interpretations (C&DIs) relating to the materiality assessment and disclosure requirements of material cybersecurity incidents under Item 1.05 of Form 8-K.
SEC Issues New Statement on Cybersecurity Incident Disclosure
June 3, 2024 | Alert | By Daniel T. Kajunski, Anne Bruno, Cynthia Larose, Raven Sun
Read about a recent statement from Erik Gerding, Director of the SEC’s Division of Corporation Finance, which provided clarification regarding the disclosure of cybersecurity incidents by reporting companies.
Reminder – T-1 Settlement Starts Today, Tuesday, May 28, 2024
May 28, 2024 | Alert | By Daniel T. Kajunski, Allyson Wilkinson
Starting today, Tuesday, May 28, 2024, the amendments to Securities Exchange Act Rule 15c6-1 take effect, shortening the settlement cycle for most broker-dealer securities transactions to the trade date plus one business day (T+1) from the trade date plus two business days (T+2). In this alert, we discuss the T+1 settlement cycle and best practices for issuers to mitigate compliance issues and reduce the risk of failed settlements.
Recent SEC Rules and Guidance Impose New Obligations on SPACs and Reverse Mergers
May 15, 2024 | Alert | By Anne Bruno, Daniel T. Kajunski, Samantha Silver
Read about how the SEC’s final rules relating to special purpose acquisition companies (SPACs) and other shell companies, which take effect on July 1, 2024, and the agency’s recent guidance on reverse mergers are likely to impact SPAC-related transactions and alternative capital raising transactions.
News & Press
Twenty-Eight Mintz Attorneys Named To Boston Magazine’s Top Lawyers List
November 22, 2022
In its second annual edition, 28 Mintz attorneys were named to Boston Magazine’s Top Lawyers list.
Mintz Represents ImmunoGen, Inc. in $200 Million Transaction
April 14, 2015
Events & Speaking
Dan is a corporate and securities attorney whose practice spans the full gamut of corporate law. He has advised clients for over two decades in public and private equity and debt financings, securities law matters, mergers and acquisitions, and strategic advice on a broad range of other corporate matters. He capably counsels public and private companies with offerings, compliance, and securities questions and leads buyers and sellers throughout the transaction process. Dan represents life sciences companies as well as clients in other technology fields, financial services, and professional services firms.
Recognition & Awards
Boston Magazine Top Lawyers – Corporate Law (2021)

